EMA validates application for Bristol-Myers’ Sprycel (dasatinib) in children with CML
Bristol-Myers Squibb announced the EMA validated its grouped Type II variation/Extension of Application for Sprycel (dasatinib) to treat children and adolescents aged 1 year to 18 years with chronic phase Philadelphia chromosome positive chronic myelogenous leukemia. May 19, 2017